Currently, the treatment of non-disseminated solid tumours is performed by surgery and irradiation. Both methods can be considered to be relatively tumour selective, without significantly harming the rest of the body. If however the tumour has disseminated to various organ sites, the metastases can be treated by chemo-or hormone therapy only. Chemotherapy has considerable side effects and a minor influence on patients' survival due to the lack of specificity of action or the induction of resistance. Hormone therapy alone has a limited tumour spectrum.
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To overcome these obvious limitations of today's treatment modalities, we tailored a fusion gene consisting of the VH and CHI Exons of a humanised MAb and the human P-glucuronidase cDNA . The product encoded by the fusion gene might be suitable for performing an antibody directed enzyme prodrug therapy (ADEPT). The concept of ADEPT as developed by Philpott et al. (1973a,b; 1974) and reemphasised by Bagshawe (1987) and Bagshawe et al. (1988) assumes that an antibody enzyme conjugate after selective localisation at the tumour target site, and its clearance from normal tissues, activates a nontoxic low molecular weight prodrug to a highly toxic drug in the tumour by enzymatic catalysis.
The therapeutic success of this approach depends on several factors:
(a) The stability of the prodrug in vivo. (j) The immunogenicity of the antibody enzyme conjugate. Despite the obvious complexity of the system, a first clinical trial with a F(ab')2 fragment of a murine anti CEA MAb chemically linked to carboxypeptidase G2 (CPG2) from Pseudomonas origin combined with a para-N (mono-2-chloroethyl monomesyl) amino benzoyl glutamic acid prodrug was performed (Bagshawe, 1991 (Bosslet et al., 1988) , its CDR-grafted (Jones et al., 1986; Riechmann et al., 1988) humanised version (Giissow & Seemann, 1991) and the cloned cDNA for human placental P-glucuronidase (Oshima et al., 1987) , a lysomal endogenous enzyme (Brot et al., 1978) . Out of these human building blocks a fusion gene was constructed . This construction was performed in analogy to the original work of Neuberger's group (Neuberger et al., 1984; Williams & Neuberger, 1986) pH 5, was added and incubated for 2 h at 37°C. The reaction was stopped using 0.2 M glycine + 0.2% SDS, pH 1 1.1. Fluorogenic units (FU) were determined as described by Glaser and Sly (1973) .
Avidity determination Avidity of fusion protein to purified CEA was determined according to Tipton et al. (1990) . The avidity to cell bound CEA was measured as described by Bosslet et al. (1988) .
Histochemical and immunohistochemical tissue specificity Transfectoma supernatants containing fusion protein were added to cryopreserved tissue sections from various human tissues for 30' at RT. After washing the selectively bound fusion protein was histochemically detected via its enzymatic catalysis resulting in a red unsoluble stain as described by Murray et al. (1989) or visualised immunohistochemically using an alkaline phosphatase labelled goat anti B-glucuronidase antibody.
Purification and analysis offusion protein BHK transfectoma supernatants containing the fusion protein were purified by anti-idiotype affinity chromatography (Bosslet et al., 1991) . Adsorption was performed at pH 7.2, elution was done at pH 4. Samples of the elution peak were analysed by SDS-PAGE under reducing or nonreducing conditions followed by silverstaining (Poehling & Neuhoff, 1981) or Western blotting (Towbin & Gordon, 1979 (Zettlmeissl et al., 1987) . A second pAB-vector containing the gene for the humanised light chain of MAb BW 431 is depicted in chart 2. The light chain gene contains the humanised V-gene of the Lchain with IgG promoter region and signal exon and the human C-kappa gene. These two vectors were cotransfected into BHK cells with the plasmid pRMH 140, carrying a neomycin resistance gene (Hudziak et al., 1982) and the plasmid pSVdhfr (Subramani et al., 1981) carrying the dihydrofolate reductase gene allowing positive selection with methotrexate (Wirth et al., 1988 fusion protein cleaves ; 12,000 moles of methylumbelliferyl P-glucuronide, the synthetic prodrug in 1 h at 37°C.
Similar turnover rates were observed using a prodrug based on daunomycin linked via a urethane nitrophenyl spacer to 13-glucuronic acid (manuscript in preparation). (Figure 1) . A schematic diagram of the two molecules is given in Figure 4a . The monovalent molecule (Figure 4b ) of a MW of 125 kDa contains the light chain of the humanised MAb BW 431 consisting of the VL and CL domains covalently linked by an interchain disulphide bond to the humanised heavy chain. The humanised heavy chain is built up by the VH and CHl domain of the humanised MAb BW 431 the N-terminal part of the human IgG3 hinge region, a linker peptide and the human P-glucuronidase. In this monovalent molecule the two hinge region cysteins form an intrachain disulfide bond. If the hinge region cysteins form two interchain disulfide bonds a bivalent fusion protein arises (Figure 4c ) which can be isolated from transfectoma supernatants at a similar amount as the monovalent fusion protein (Figure 4c ). Under native conditions the two molecular forms exist as bivalent molecules (Figure 4d ) as shown by gel chromatography under non denaturing conditions.
Furthermore, the mild elution conditions applicable to the anti-idiotype affinity chromatography resulted in the isolation of a protein fraction with satisfying biochemical properties. Avidity to CEA was found by two independent methods to be in the range of 101 I Mol', a figure similar to the avidity of the murine MAb BW 431 or its humanised version (Table  I) . Since the molecular forms of the fusion protein as revealed under denaturing conditions are associated in the native state forming molecules with two identical binding sites, the avidity measurements refer to the binding strength of bivalent molecules. In addition, the histochemical and immunohistochemical tissue specificity of the fusion protein was not distinguishable from that of the murine MAb BW 431 (Table  II) . Not only the binding portion of the fusion protein was functionally active, but also the enzyme moiety showed a catalytic activity and pH profile similar to human P-glucuronidase (Brot et al., 1978) . Despite the fact that the catalytic optimum of the fusion protein is at pH 4.5 and the turnover rate at pH 7.0, a pH value assumed for human solid tumours (Tannock & Ratin, 1989) , is about 20% of the optimal rate it still seems to be high enough to fulfill the assumptions made in the ADEPT concept. Due to its fully human or humanised building blocks, the fusion protein should have a low immunogenicity in humans, if at all. This characteristic should allow the long term application of this molecule in humans and distinguishes this construct from xenogeneic mouse antibody -bacterial enzyme conjugates which were reported to elicit a fast neutralising antibody response in the patient (Bagshawe et al., 1991) . Before the fusion protein can be considered for clinical evaluation, its pharmacodynamic (Natowicz et al., 1979) in relation to the carbohydrate content (Stahl et al., 1976) and therapeutic effects combined with appropriately designed prodrugs (Stella et al., 1985) must be studied in further preclinical model systems. Prodrug systems which are investigated presently are glucuronides of daunomycin and adriamycin. To our knowledge, this is the first report, describing a functionally active fusion protein, consisting of a humanised tumour selective binding portion and a human lysosomal enzyme with potential applicability for a more selective tumour therapy. 
